证券代码：000710 证券简称：贝瑞基因 公告编号：2025-056 传真：010-84306824 成都市贝瑞和康基因技术股份有限公司 关于变更证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）董事会于近日 收到通知，公司证券事务代表宋晓凤女士因合同期满，不再担任公司证券事务代 表职务及其他职务。根据《中华人民共和国公司法》（以下简称《公司法》）《公 司章程》等相关规定，该通知自送达公司董事会之日起生效。截至本公告披露日， 宋晓凤女士未持有公司股份，不涉及应履行而未履行完毕的公开承诺。宋晓凤女 士在担任证券事务代表期间勤勉尽责，公司董事会对宋晓凤女士在任职期间为公 司做出的贡献表示衷心感谢！ 2025年10月30日，公司召开第十届董事会第十八次会议，审议通过了《关于 变更证券事务代表的议案》，同意聘任王一迪女士为公司证券事务代表，任期自 董事会审议通过之日起至第十届董事会任期届满之日止。 王一迪女士（简历见附件）已取得深圳证券交易所颁发的《董事会秘书资格 证书》，其任职资格符合《公司法 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-058 成都市贝瑞和康基因技术股份有限公司 关于2025年前三季度计提资产减值准备的公告 根据《企业会计准则》和公司相关会计政策，公司对于以摊余成本计量的金融 资产、以公允价值计量且其变动计入其他综合收益的债务工具投资、租赁应收款、 合同资产和财务担保合同等，以预期信用损失为基础确认损失准备。公司考虑有关 过去事项、当前状况以及对未来经济状况的预测等合理且有依据的信息，以发生违 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 根据《深圳证券交易所股票上市规则》的相关规定，成都市贝瑞和康基因技术 股份有限公司（以下简称"本公司"或"公司"）依据《企业会计准则》及公司相 关会计政策的规定，将公司 2025 年前三季度计提资产减值准备的具体情况公告如下： 一、本次计提资产减值准备概述 为了真实、准确地反映公司 2025 年前三季度的财务状况和经营成果，公司依据 《企业会计准则》以及公司相关会计政策的规定，对应收账款、其他应收款、在建 工程、固定资产、长期股权投资、存货跌价损失及合同履约成本等各项资产 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-057 成都市贝瑞和康基因技术股份有限公司 关于全资子公司调整产业园租赁事项的公告 2、甲乙双方协商一致，将新投生物科技产业园北区整体园区（即9-13号楼， 含地下车位）用于产教融合基地招商使用，并临时变更部分楼宇的新型工业用地 功能为产教融合基地功能，其中产业园北区10#楼、11#楼整栋及12#楼的3-5层部 分面积约2.5万平方米为原合同（2024-004）项下由乙方租赁部分。现双方经协 商一致，缩减原合同（2024-004）项下租赁面积，乙方不再租赁新投生物科技产 业园10#楼、11#楼整栋及12#楼的3-5层部分面积约2.5万平方米（简称"减租面 积"），并将减租面积调整至甲方控股股东福州滨海临空开发建设有限公司开发 的福州新区生物医药产业园一期，由乙方设立的福建贝瑞和康产业孵化器有限公 司负责承租。双方就拟变更原合同（2024-004）项下的租赁房屋范围事宜约定如 下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、产业园租赁事项概述 成都市贝瑞和康基因技术股份有限公司（以下简称" ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-059 成都市贝瑞和康基因技术股份有限公司 第十届监事会第十一次会议决议。 第十届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第十一次会议于 2025 年 10 月 30 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场会议的方式召开，会议通知已于 2025 年 10 月 28 日以邮件形式发 送给各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。本次监事 会会议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李翔东先生 主持，董事会秘书列席了会议。会议的召开和表决程序符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 二、审议情况 1、审议通过《2025 年第三季度报告》 表决结果：3 票同意，0 票反对，0 票弃权。 监事会审阅了《2025 年第三季度报告》，认为其内容真实、准确、完整， 不存在任何的虚假记载、误导性陈述或者 ...

Market Overview - The medical services sector experienced a decline of 0.9% on October 22, with Sanbo Brain Science leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the medical services sector included: - Yaokang Biological (688046) with a closing price of 17.18, up 2.81% [1] - Aoyang Health (002172) with a closing price of 4.26, up 1.91% [1] - Haochen Medical (002622) with a closing price of 3.32, up 1.84% [1] - Significant decliners included: - Sanbo Brain Science (301293) with a closing price of 57.19, down 4.67% [2] - Chengda Pharmaceutical (301201) with a closing price of 33.98, down 4.50% [2] - XD Haoyuan Medical (688131) with a closing price of 79.90, down 2.07% [2] Capital Flow - The medical services sector saw a net outflow of 615 million yuan from institutional investors, while retail investors contributed a net inflow of 370 million yuan [2][3] - Key stocks with notable capital flows included: - Kanglong Chemical (300759) with a net inflow of 46.59 million yuan from institutional investors [3] - Aoyang Health (002172) with a net inflow of 10.44 million yuan from institutional investors [3] - Yaokang Biological (688046) with a net inflow of 9 million yuan from institutional investors [3]

Core Insights - The medical services sector experienced a rise of 1.53% on October 21, with He Yuan Biological leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Medical Services Sector Performance - He Yuan Biological (688238) closed at 7.78, with an increase of 8.21% and a trading volume of 282,000 shares, amounting to 217 million yuan [1] - Other notable performers included Bei Rui Gene (000710) with a closing price of 13.22, up 3.77%, and Yao Kang Biological (688046) at 16.71, up 3.66% [1] - The sector saw a total net inflow of 250 million yuan from main funds, while retail investors experienced a net outflow of approximately 74 million yuan [2] Fund Flow Analysis - Major net inflows were observed in companies like Yao Ming Kang De (603259) with 353 million yuan, while retail investors showed significant outflows [3] - The top three companies by main fund inflow were Yao Ming Kang De (603259), Kang Long Hua Cheng (300759), and Hao Yuan Medical (688131) [3] - Retail investors showed a negative trend in several companies, indicating a cautious sentiment in the market [3]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-052 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人所持公司股份被司法拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖标的物为成都市贝瑞和康基因技术股份有限公司（以下简称 "贝瑞基因"或"公司"）控股股东之一致行动人侯颖女士持有的本公司 400,000 股股票，占其持有公司股份的比例为 100.00%，占公司总股本的比例 为 0.11%。上述被司法拍卖的股份为无限售流通股，已被全部质押和司法再冻 结。 2、在本次拍卖事项中，所涉 400,000 股股份为第二次司法拍卖，最终流 拍。流拍股份将依据成渝金融法院后续裁定进行处置，公司将持续关注后续 进展并根据相关法律法规的规定履行信息披露义务。 3、公司目前生产经营情况正常，该事项未对公司正常经营活动产生重大 影响。 一、本次司法拍卖的基本情况 | 股 | 是否为控 | 拍 | 本次被司 | 占其所 | 占公司 | 是否 | 东 | 股股东及 | 拍卖 | 卖 | | | | --- | --- ...

Core Viewpoint - Berry Genomics (000710) has announced that its subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its α and β thalassemia gene testing kit, marking a significant milestone in the clinical application of third-generation sequencing technology [1] Group 1 - The gene testing kit utilizes single-molecule sequencing technology for the qualitative detection of thalassemia gene mutations in human peripheral venous whole blood samples [1] - The certification of the testing kit represents a critical breakthrough in both technology and strategy for Berry Genomics, facilitating the clinical transformation of its third-generation sequencing technology [1]

Core Insights - Berry Genomics (000710.SZ) announced that its subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its α and β-thalassemia gene testing kit using single-molecule sequencing technology, marking a significant milestone in the clinical application of third-generation sequencing technology [1] Group 1 - The testing kit represents a critical breakthrough in technology and strategy for Berry Genomics, facilitating the transition from gene testing services to a high-value model that integrates "equipment + reagents + intelligent analysis" [1] - The kit utilizes CATSA technology and single-molecule real-time (SMRT) high accuracy (HiFi) mode to achieve "one-step" detection of all mutation types of α and β-thalassemia, addressing traditional testing limitations and detection gaps [1] - The AI data analysis platform, validated by 300,000 samples, completes the "testing technology - data processing - clinical report" closed loop, enhancing the overall efficiency and reliability of the testing process [1] Group 2 - The successful registration of the testing kit strengthens the systematic layout of "research - hardware - products," accelerating the company's strategic upgrade and laying a solid product foundation for establishing a "Chinese solution" for third-generation sequencing [1]

Core Viewpoint - Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its α and β thalassemia gene testing kit, marking a significant breakthrough in the clinical application of third-generation sequencing technology [1] Group 1 - The gene testing kit utilizes single-molecule sequencing to qualitatively detect mutations in thalassemia genes from human peripheral venous whole blood samples [1] - The kit specifically identifies four deletions and three point mutations in the α-globin gene, as well as sixteen point mutations in the β-globin gene [1] - The acquisition of the registration certificate enhances the systematic layout of the company's "research - hardware - product" strategy, laying a product foundation for establishing a "Chinese solution" for third-generation sequencing [1]